Literature DB >> 27198513

Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Patricia A Cronin1, Cristina Olcese1, Sujata Patil2, Monica Morrow1, Kimberly J Van Zee3.   

Abstract

BACKGROUND: Age is a known risk factor for recurrence in women with ductal carcinoma in situ (DCIS) treated with breast-conserving surgery (BCS). We explored the relationship between age, other risk factors, and recurrence.
METHODS: Using a prospectively maintained database of DCIS patients undergoing BCS from 1978 to 2010, the association of age and recurrence risk was analyzed using Kaplan-Meier estimates, multivariable analysis, and competing risk multivariable analysis.
RESULTS: Overall, 2996 cases were identified. Median follow-up for those without recurrence was 75 months; 732 were followed for ≥10 years, and 363 (12 %) had recurrence [192 (53 %) DCIS, 160 (44 %) invasive, 11 (3 %) unknown]. Risk of recurrence decreased with age, even after adjustment for eight clinicopathologic variables on multivariable analysis [hazard ratios (HR), with <40 years of age as the reference: 40-49 years, 0.82 (p = 0.36), 50-59 years, 0.46 (p = 0.0005), 60-69 years, 0.50 (p = 0.003), 70-79 years, 0.56 (p = 0.02), ≥80 years, 0.21 (p = 0.0015)]. This association persisted for cohorts with and without radiation therapy. Using competing risk multivariable analysis, the effect of age on invasive recurrence was empirically stronger than for DCIS recurrence. Ten-year invasive recurrence was 16 and 6.5 % in women <40 years of age and women ≥40 years of age, respectively. Only 0.6 % of the population ultimately developed distant disease; those <40 years of age constituted 4.7 % (141/2996) of the population, but 21 % (4/19) of those developed distant disease.
CONCLUSIONS: The risk of recurrence of DCIS decreases with age. This effect is particularly strong at the extremes of age and is independent of other clinicopathologic factors. The oldest women are at low risk of recurrence, while the youngest women have a higher overall, and especially invasive, recurrence rate, although mortality remains low. These findings should be incorporated into risk/benefit discussions of treatment options.

Entities:  

Mesh:

Year:  2016        PMID: 27198513      PMCID: PMC4995886          DOI: 10.1245/s10434-016-5249-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

1.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

Authors:  B Fisher; J Dignam; N Wolmark; E Mamounas; J Costantino; W Poller; E R Fisher; D L Wickerham; M Deutsch; R Margolese; N Dimitrov; M Kavanah
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

2.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

Authors:  Steven A Narod; Javaid Iqbal; Vasily Giannakeas; Victoria Sopik; Ping Sun
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

3.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age.

Authors:  K J Van Zee; L Liberman; B Samli; K N Tran; B McCormick; J A Petrek; P P Rosen; P I Borgen
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

5.  Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007.

Authors:  Katharine Yao; Andrew K Stewart; David J Winchester; David P Winchester
Journal:  Ann Surg Oncol       Date:  2010-05-12       Impact factor: 5.344

6.  Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the Breast Cancer Surveillance Consortium.

Authors:  Kimberly H Allison; Linn A Abraham; Donald L Weaver; Anna N A Tosteson; Heidi D Nelson; Tracy Onega; Berta M Geller; Karla Kerlikowske; Patricia A Carney; Laura E Ichikawa; Diana S M Buist; Joann G Elmore
Journal:  Cancer       Date:  2015-01-20       Impact factor: 6.860

7.  Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience.

Authors:  Bruno Cutuli; Christine Cohen-Solal-le Nir; Brigitte de Lafontan; Hervé Mignotte; Virginie Fichet; Renaud Fay; Véronique Servent; Sylvia Giard; Claire Charra-Brunaud; Claire Lemanski; Hugues Auvray; Stéphane Jacquot; Jean-Christophe Charpentier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

8.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.

Authors:  Todd M Tuttle; Stephanie Jarosek; Elizabeth B Habermann; Amanda Arrington; Anasooya Abraham; Todd J Morris; Beth A Virnig
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

Review 9.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010

10.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Authors:  Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George
Journal:  Lancet Oncol       Date:  2010-12-07       Impact factor: 41.316

View more
  15 in total

1.  Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.

Authors:  Megan E Miller; Shirin Muhsen; Emily C Zabor; Jessica Flynn; Cristina Olcese; Dilip Giri; Kimberly J Van Zee; Melissa Pilewskie
Journal:  Ann Surg Oncol       Date:  2019-09-24       Impact factor: 5.344

2.  Response to Habel and Buist.

Authors:  Marc D Ryser; E Shelley Hwang
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

3.  ASO Author Reflections: Does Genomic Testing of DCIS Provide Added Value? And Is It Worth the Cost?

Authors:  Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2019-08-23       Impact factor: 5.344

4.  Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.

Authors:  Anita Mamtani; Faina Nakhlis; Stephanie Downs-Canner; Emily C Zabor; Monica Morrow; Tari A King; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2019-08-22       Impact factor: 5.344

Review 5.  Controversies in the Treatment of Ductal Carcinoma in Situ.

Authors:  Andrea V Barrio; Kimberly J Van Zee
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

6.  Wherein the authors attempt to minimize the confusion generated by their study "Breast cancer mortality after a diagnosis of ductal carcinoma in situ" by several commentators who disagree with them and a few who don't: a qualitative study.

Authors:  S A Narod; H Ahmed; V Sopik
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

7.  ASO Author Reflections: Advising a Woman with Ductal Carcinoma In Situ Regarding Various Treatment Options-A Complex Decision.

Authors:  Anita Mamtani; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2019-09-23       Impact factor: 5.344

8.  Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?

Authors:  Megan E Miller; Shirin Muhsen; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

9.  Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.

Authors:  Sasha R Halasz; Thomas O'Keefe; Anne M Wallace; Sarah L Blair
Journal:  Breast Cancer Res Treat       Date:  2020-11-12       Impact factor: 4.872

10.  Treatment of Ductal Carcinoma in Situ: Considerations for Tailoring Therapy in the Contemporary Era.

Authors:  Anita Mamtani; Kimberly J Van Zee
Journal:  Curr Breast Cancer Rep       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.